Belite Bio (NASDAQ:BLTE – Get Free Report) issued its earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02), Zacks reports.
Belite Bio Price Performance
NASDAQ:BLTE opened at $67.44 on Monday. Belite Bio has a one year low of $31.01 and a one year high of $86.53. The company has a market cap of $2.15 billion, a PE ratio of -60.76 and a beta of -1.54. The firm’s 50 day simple moving average is $58.40 and its 200 day simple moving average is $60.33.
Analyst Upgrades and Downgrades
Separately, Benchmark boosted their target price on shares of Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a research report on Tuesday, January 21st.
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Recommended Stories
- Five stocks we like better than Belite Bio
- Investing in Construction Stocks
- Maximize Your Dividends With These 3 High-Yield ETFs
- What is a Death Cross in Stocks?
- 3 Undervalued Stocks Poised for a Strong Comeback
- How Technical Indicators Can Help You Find Oversold Stocks
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
